甘李药业: 2025年半年度报告摘要

Core Viewpoint - Ganlee Pharmaceutical Co., Ltd. reported significant growth in revenue and profit for the first half of 2025, indicating strong operational performance despite a slight decrease in total assets compared to the previous year [1]. Group 1: Financial Performance - Total assets at the end of the reporting period were approximately ¥11.88 billion, a decrease of 1.37% from the previous year [1]. - Revenue for the reporting period reached ¥2.07 billion, representing a 57.18% increase compared to the same period last year [1]. - Total profit amounted to approximately ¥691 million, showing a substantial increase of 102.73% year-on-year [1]. - Net profit attributable to shareholders was approximately ¥488 million, which is a remarkable increase of 284.47% compared to the same period last year [1]. Group 2: Shareholder Information - The total number of shareholders at the end of the reporting period was 77,299 [2]. - The largest shareholder, Gan Zhongru, holds 34.21% of the shares, amounting to approximately 205.64 million shares [2]. - Other significant shareholders include Beijing Xutong Hongda Technology Co., Ltd. with 5.90% and Hong Kong Central Clearing Limited with 1.25% [2].